Maternal Serum ADAM-12 as a Potential Marker for Different Adverse Pregnancy Outcomes

Abstract

Objective: To investigate first-trimester ADAM-12 levels in pregnancies which later develop hypertensive and growth complications. Methods: First-trimester serum samples (11⁺⁰ to 13⁺⁶ weeks) were retrieved from frozen storage. 47 samples with at least one of the following adverse outcomes: pre-eclampsia (PE), small for gestational age, HELLP syndrome and gestational hypertension were analysed and 452 controls matched to the cases by gestational age and length of storage were analysed. ADAM-12 levels were measured by the automated AutoDELFIA immunoassay platform. Results: ADAM-12 was found to increase with gestational age (11⁺⁰ to 13⁺⁶ weeks) and decrease with increasing maternal weight and in women who smoked. After correction, ADAM-12 median multiples of the median were increased in cases with HELLP syndrome, all PE and PE only. Conclusion: The increased first-trimester levels of ADAM-12 in PE and HELLP are in contrast with previous findings. The usefulness of ADAM-12 as a marker for adverse outcomes is still unclear.

Mid-Trimester Maternal ADAM12 Levels Differ According to Fetal Gender in Pregnancies Complicated by Preeclampsia

“…The authors, however, commented that smoking and maternal age accounted for the largest intergroup differences in ADAM12, whereas gender-related differences were negligible. 28 The data regarding changes in ADAM12 in early pregnancy are conflicting [17][18][19][20]29 with previous studies reporting a downregulation of ADAM12 in pregnancies subsequently complicated by preeclampsia and more recent reports suggesting an upregulation. Some of these disparities may relate to different sampling methods, particularly different gestational ages.…”

“…Much of the data on early pregnancy biomarkers is conflicting, [17][18][19][20] with several studies reporting positive and negative findings for the same markers. We have previously identified the biomarkers placental growth factor (PlGF), soluble endoglin (sEng), metallopeptidase domain 12 (ADAM12), and insulinlike growth factor acid labile subunit (IGFALS) as being relevant to the prediction of preeclampsia and FGR.…”

Consejería genética y diagnóstico prenatal: recomendaciones y futuras perspectivas para Colombia

“…La determinación de una población en riesgo a partir del tamizaje prenatal indica que en mujeres de 35 años o mayores al momento del parto, personas con antecedentes familiares positivos para malformaciones o síndromes genéticos conocidos, se hace de mayor relevancia la aplicación procedimientos diagnósticos prenatales (31)(32). Los avances tecnológicos en imágenes diagnósticas, como también en el área de la citogenética (33) y genómica (34) proporcionan con mayor precisión el diagnóstico genético prenatal (35).…”

Maternal Serum ADAM-12

“…In it, Matwejew et al [1] concluded that 'The usefulness of ADAM-12 as a marker for adverse outcomes is still unclear.' Indeed, the clinical usefulness of maternal serum ADAM-12 is proposed in some disorders such as pre-eclampsia [2] and Down syndrome [3] .…”